148 related articles for article (PubMed ID: 38332982)
1. Significant Prognostic Factor at Age Cut-off of 73 Years for Advanced Ovarian Serous Cystadenocarcinoma Patients: Insights from Real-World Study.
Zhang K; Feng S; Wang Y; Feng W; Shen Y
Int J Womens Health; 2024; 16():203-218. PubMed ID: 38332982
[TBL] [Abstract][Full Text] [Related]
2. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
Tang F; Lu Z; He C; Zhang H; Wu W; He Z
BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
[TBL] [Abstract][Full Text] [Related]
3. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
4. Mining TCGA database for gene expression in ovarian serous cystadenocarcinoma microenvironment.
Xu Y; Xu Y; Wang C; Xia B; Mu Q; Luan S; Fan J
PeerJ; 2021; 9():e11375. PubMed ID: 33987033
[TBL] [Abstract][Full Text] [Related]
5. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
[TBL] [Abstract][Full Text] [Related]
6. A Novel Hypoxia-Related Gene Signature with Strong Predicting Ability in Non-Small-Cell Lung Cancer Identified by Comprehensive Profiling.
Yang H; Wang Z; Gong L; Huang G; Chen D; Li X; Du F; Lin J; Yang X
Int J Genomics; 2022; 2022():8594658. PubMed ID: 35634481
[TBL] [Abstract][Full Text] [Related]
7. Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
Kim J; Chang Y; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2019 Jan; 30(1):e11. PubMed ID: 30479095
[TBL] [Abstract][Full Text] [Related]
8. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
10. KEGG-expressed genes and pathways in triple negative breast cancer: Protocol for a systematic review and data mining.
Chen J; Liu C; Cen J; Liang T; Xue J; Zeng H; Zhang Z; Xu G; Yu C; Lu Z; Wang Z; Jiang J; Zhan X; Zeng J
Medicine (Baltimore); 2020 May; 99(18):e19986. PubMed ID: 32358373
[TBL] [Abstract][Full Text] [Related]
11. A Competing Nomogram to Predict Survival Outcomes in Invasive Micropapillary Breast Cancer.
Li D; Zhong C; Cheng Y; Zhu N; Tan Y; Zhu L; Xu D; Yuan Y
J Cancer; 2019; 10(27):6801-6812. PubMed ID: 31839814
[No Abstract] [Full Text] [Related]
12. A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.
Xiong DD; Qin Y; Xu WQ; He RQ; Wu HY; Wei DM; Zeng JJ; Dang YW; Chen G
Clin Drug Investig; 2018 Oct; 38(10):909-925. PubMed ID: 30097905
[TBL] [Abstract][Full Text] [Related]
13. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
Zuo L; Li X; Tan Y; Zhu H; Xiao M
J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
[TBL] [Abstract][Full Text] [Related]
14. Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer.
Yin LK; Yuan HY; Liu JJ; Xu XL; Wang W; Bai XY; Wang P
World J Clin Cases; 2023 Jul; 11(20):4763-4787. PubMed ID: 37584004
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel candidate genes and small molecule drugs in ovarian cancer by bioinformatics strategy.
Wei M; Bai X; Dong Q
Transl Cancer Res; 2022 Jun; 11(6):1630-1643. PubMed ID: 35836518
[TBL] [Abstract][Full Text] [Related]
16. Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses.
Wu Y; Xia L; Guo Q; Zhu J; Deng Y; Wu X
Cancer Manag Res; 2020; 12():5213-5223. PubMed ID: 32636682
[TBL] [Abstract][Full Text] [Related]
17. Identification of critical genes in gastric cancer to predict prognosis using bioinformatics analysis methods.
Liu J; Ma L; Chen Z; Song Y; Gu T; Liu X; Zhao H; Yao N
Ann Transl Med; 2020 Jul; 8(14):884. PubMed ID: 32793728
[TBL] [Abstract][Full Text] [Related]
18. Construction of monocyte-related prognosis model based on comprehensive analysis of bulk RNA-seq and single-cell RNA-seq in high-grade serous ovarian cancer.
Xu Y; Tan S; Huang W; Wang YX
Medicine (Baltimore); 2023 Dec; 102(50):e36548. PubMed ID: 38115318
[TBL] [Abstract][Full Text] [Related]
19. 2 years is a reasonable age cut-off level for prognostic assessment of children with hepatoblastoma.
Lin YB; Huang SH; Liu S
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10553-10562. PubMed ID: 37975379
[TBL] [Abstract][Full Text] [Related]
20. A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer.
Zong S; Xu PP; Xu YH; Guo Y
J Ovarian Res; 2022 Aug; 15(1):90. PubMed ID: 35915456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
